20:51 , Mar 23, 2017 |  BC Week In Review  |  Clinical News

AEVI-001: Ph II/III SAGA data

Top-line data from the double-blind, U.S. Phase II/III SAGA trial in 96 evaluable ADHD patients ages 12-17 with genetic disorders impacting mGluRs showed that twice-daily oral AEVI-001 missed the primary endpoint of reducing ADHD-RS total...
22:39 , Mar 20, 2017 |  BC Extra  |  Clinical News

Aevi plummets after ADHD candidate fails in Phase II/III

Aevi Genomic Medicine Inc. (NASDAQ:GNMX) shed $3.23 (59%) to $2.21 on Monday after it said AEVI-001 missed the primary endpoint in the Phase II/III SAGA study to treat ADHD in adolescent patients with metabotropic glutamate...
21:45 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

AEVI-001: Ph I/II started

Aevi began an open-label, U.S. Phase I/II trial evaluating 50, 100, 200 and 400 mg oral AEVI-001 twice daily over 5 weeks in about 12 patients ages 12-17 with a 22q11.2 deletion and diagnosed with...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

NFC-1: Phase II/III started

Medgenics began the double-blind, placebo-controlled, U.S. Phase II/III SAGA trial to evaluate 100, 200 and 400 mg oral NFC-1 twice daily for 6 weeks in 90 patients ages 12-17. In 1H17, Medgenics plans to start...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

neuroFix Therapeutics, Medgenics deal

Medgenics acquired neuroFix for $2 million in cash and more than $481 million in potential milestones. neuroFix is eligible to receive $6 million in cash and stock upon the earlier of the completion of an...
07:00 , Aug 29, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Photoreceptor replacement therapy for degenerative retinal disease Embryonic stem cell (ESC)-derived photoreceptors could help treat degenerative retinal diseases. In an adapted...
08:00 , Jan 5, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Attention deficit hyperactivity disorder (ADHD) Metabotropic glutamate receptor subtype 5 (mGluR5; GRM5); mGluR7 (GRM7); mGluR8 (GRM8) A genomewide association study suggests agonizing mGluR5, mGluR7 or...
08:00 , Jan 5, 2012 |  BC Innovations  |  Targets & Mechanisms

Fine-tuning mGluRs

Studies by two American teams have converged on a family of metabotropic glutamate receptors as players in attention deficit hyperactivity disorder and autism spectrum disorder. 1,2 The findings build an argument for agonizing the receptors...
07:00 , Aug 12, 2010 |  BC Innovations  |  Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche 's Genentech Inc. unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease. 1 Nineteen of the 112 candidate...